Please login to the form below

Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds

Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.

By Jennifer Blainey, Director, Hanover Health

By creating England’s first Women’s Health Strategy, the Government has signalled its intention to take seriously the healthcare needs of women and crucially, make ordinary women central in these discussions. If this strategy is to succeed it will need to ensure it does more than listen but delivers a plan that ensures 51% of the population is properly represented in clinical trials and service design. In a society which is so interconnected it is in everyone’s interests to have women’s health improved, not just for women themselves.

In the press release accompanying the consultation Health Secretary, Matt Hancock, stated, ‘For generations women have lived with a healthcare system that is mostly designed for men, by men’. Caroline Criado-Perez in her book “Invisible Women” captured multiple examples of how the world, including healthcare, is designed for men. Her book points out that as we move towards a world led by data, women are missing from the sources being used to inform those datasets. An article in the British Medical Journal (BMJ)1 in October 2020 found:

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use has not recognised the need for specific, standalone guidelines on the inclusion of women, continuing to refer to women as a special subgroup to be considered when appropriate. Journals inconsistently publish sex disaggregated data on drug efficacy, safety, and toxicity, and industry rarely reports sex or gender differences on product labels. Fragmented action and resistance perpetuates and extends women's exclusion from timely, safe, and quality of life enhancing therapeutic options across their lives.

It would be a huge leap forward if the Health Strategy for England could improve the representation of women in pharmaceutical research. This is particularly pertinent now the pandemic has awoken governments to the public health and economic resilience strong data can provide. As countries turn to dealing with “long Covid”, the term for a range of longer-term health issues suffered by those who have had the virus, which seems to disproportionately effect women,2 more diverse clinical trials will be vital.

The Health Secretary’s decision to create a Women’s Health Strategy for England is the right one. It is even better that it seeks input from individual women and groups to inform how it develops through its public survey. What has become clear over the last year is that people from different backgrounds experience our public services differently. That experience cannot be represented and understood without seeking counsel from a broad range of service users.

The importance of getting this right also shouldn’t be underestimated. Earlier this year a report found black women are still four times more likely to die in childbirth or pregnancy than white women in the UK.3 The Eve Appeal, a charity for gynaecological cancers, found in a survey of healthcare professionals that 47% agreed that women not knowing the correct terminology for their reproductive anatomy could lead to delayed diagnosis of a gynaecological cancer.4 Menopausal women are now the fastest growing demographic in the workplace yet one in four considers leaving work due to the symptoms.5

This strategy isn’t just a nice to have, a way for the Government to appeal to women voters. Women are unnecessarily dying in childbirth or from cancers they were too embarrassed to discuss. Women are leaving the workforce because they don’t understand a natural though challenging part of ageing. All of this is bad for the economy and wider society. The pandemic has demonstrated in an all too clear manner how interconnected we all are in society. No woman or man is an island.

If this strategy can go some way to addressing problems in public services and public attitudes to women’s health, including in the workplace, then that will bring benefits to everyone. The mother who is alive to look after her child. The woman who survives because they caught her cancer early because she had the confidence and language to explain her symptoms. The woman who is supported by her employer through all of the life stages of womanhood. More effective medicines and medical interventions created because women were included in clinical trials.

The Women’s Health Strategy might be aimed at addressing long overdue issues for 51% of the population but 100% of society stands to benefit from it. It has never been a man’s world, let’s hope this strategy helps to shape our public services and society to reflect that fact.


7th April 2021


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

70 Gray's Inn Road
United Kingdom

Latest content on this profile

Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications
COVID-19 has changed the way we must talk about treatment for rare diseases
The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.
Hanover Communications
What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.
Hanover Communications
It's out - so what?
The European Commission’s Pharmaceutical Strategy has been published and the Commission has presented its priorities for the coming years. The focus is on patient access to affordable treatments; ensuring and boosting the competitiveness of the European pharmaceutical sector and making sure that the EU will have a strong voice on global health and pharmaceutical policy. Stakeholders now need to make sure that their voices are heard and included in upcoming proposals and, eventually, in legislation. By Jenni Kortelainen, Hanover EU
Hanover Communications
Let's be ambitious for patients and life sciences investment in Global Britain
“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.
Hanover Communications